Abeona Therapeutics Inc. (0H7R.L)
USD 4.84
(8.52%)
USD 4.84
(8.52%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.4 Million USD | -42.28% |
| 2022 | 7.62 Million USD | -18.67% |
| 2021 | 9.37 Million USD | 7.41% |
| 2020 | 8.73 Million USD | 9.82% |
| 2019 | 7.95 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 400 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 23.16 Million USD | -0.02% |
| 2024 Q1 | 23.16 Million USD | 329.06% |
| 2023 Q3 | 5.69 Million USD | -4.72% |
| 2023 Q1 | 7.31 Million USD | -4.04% |
| 2023 FY | 5.4 Million USD | -29.2% |
| 2023 Q2 | 5.97 Million USD | -18.38% |
| 2023 Q4 | 5.4 Million USD | -5.13% |
| 2022 Q1 | 9.09 Million USD | -3.02% |
| 2022 FY | 7.62 Million USD | -18.67% |
| 2022 Q4 | 7.62 Million USD | -8.04% |
| 2022 Q3 | 8.29 Million USD | -2.82% |
| 2022 Q2 | 8.53 Million USD | -6.16% |
| 2021 FY | 9.37 Million USD | 7.41% |
| 2021 Q1 | 8.46 Million USD | 20.66% |
| 2021 Q3 | 6.16 Million USD | -24.82% |
| 2021 Q4 | 9.37 Million USD | 52.12% |
| 2021 Q2 | 8.19 Million USD | -3.16% |
| 2020 Q1 | 6.01 Million USD | -3.81% |
| 2020 FY | 8.73 Million USD | 9.82% |
| 2020 Q2 | 7.52 Million USD | 25.16% |
| 2020 Q3 | 7.27 Million USD | -3.34% |
| 2020 Q4 | 7.01 Million USD | -3.53% |
| 2019 Q4 | 6.25 Million USD | -3.56% |
| 2019 FY | 7.95 Million USD | 0.0% |
| 2019 Q3 | 6.48 Million USD | -3.37% |
| 2019 Q2 | 6.7 Million USD | -3.16% |
| 2019 Q1 | 6.92 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | 250 Thousand USD | 0.0% |
| 2014 FY | 400 Thousand USD | 0.0% |
| 2014 Q4 | 400 Thousand USD | 60.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.987% |
| Dynavax Technologies Corporation | 256.91 Million USD | 98.287% |
| Illumina, Inc. | 2.26 Billion USD | 99.805% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.969% |
| Biogen Inc. | 7.33 Billion USD | 99.94% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -340.2% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.797% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 99.685% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 89.4% |
| Waters Corporation | 2.35 Billion USD | 99.813% |
| Perrigo Company plc | 4.07 Billion USD | 99.892% |
| uniQure N.V. | 138.4 Million USD | 96.82% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 92.276% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 99.011% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 92.394% |
| bluebird bio, Inc. | 330.32 Million USD | 98.667% |
| Cara Therapeutics, Inc. | 43.16 Million USD | 89.802% |
| Imunon, Inc. | 1.13 Million USD | -286.38% |
| Myriad Genetics, Inc. | 145 Million USD | 96.964% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 98.972% |
| Nektar Therapeutics | 230.4 Million USD | 98.089% |
| Editas Medicine, Inc. | 36.53 Million USD | 87.952% |
| Verastem, Inc. | 41.55 Million USD | 89.407% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.954% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | 78.922% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 97.467% |
| Unity Biotechnology, Inc. | 26.99 Million USD | 83.69% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 99.612% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | 88.447% |
| Evolus, Inc. | 126.54 Million USD | 96.521% |
| Adicet Bio, Inc. | 17.7 Million USD | 75.134% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -43.201% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.837% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.186% |
| FibroGen, Inc. | 170.45 Million USD | 97.418% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 99.839% |
| OPKO Health, Inc. | 326.56 Million USD | 98.652% |
| Homology Medicines, Inc. | 44.05 Million USD | 90.008% |
| Geron Corporation | 85.89 Million USD | 94.875% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 99.816% |
| Exelixis, Inc. | 189.94 Million USD | 97.682% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -249.365% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 96.184% |
| Zoetis Inc. | 6.8 Billion USD | 99.935% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 97.638% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 99.455% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 87.881% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 99.697% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -2815.232% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.706% |
| Blueprint Medicines Corporation | 774.12 Million USD | 99.431% |
| Insmed Incorporated | 1.2 Billion USD | 99.634% |
| TG Therapeutics, Inc. | 110.79 Million USD | 96.027% |
| Incyte Corporation | 38.28 Million USD | 88.503% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 99.498% |